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Colocalisation of matrix metalloproteinase-9-mRNA and protein in human
colorectal cancer stromal cells
ZS Zeng and JG Guillem
Colorectal Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, USA.
Summary The matrix metalloproteinases (MMPs) are perceived as essential for tumour invasion and
metastases. The purpose of this study was to determine the expression and cellular localisation of the 92 kDa
type IV collagenase (MMP-9) protein and mRNA in human colorectal cancer (CRC). In CRC and matched
normal mucosa specimens from 26 CRC patients, Northern blot hybridisation and Western blot analyses
provide convincing evidence that MMP-9 is expressed in greater quantities in CRC than in normal tissue. The
MMP-9 tumour to normal mucosa fold-increase (T/N) was 9.7+7.1 (mean+s.d.) (P<0.001) for RNA and
7.1 +3.9 (P< 0.001) for protein. The sites of MMP-9 mRNA and protein synthesis were colocalised in tumour
stroma by in situ hybridisation and immunohistochemistry in 26 CRC samples. Both MMP-9 mRNA and
protein signals were strongest in the population of stromal cells concentrated at the tumour-stroma interface
of an invading tumour. Furthermore, MMP-9-positive cells were identified as macrophages using an anti-
macrophage antibody (KP1) in serial sections from ten CRC samples. Given the persistent localisation of
MMP-9-producing macrophages to the interphase between CRC and surrounding stroma, our observations
suggest that MMP-9 production is controlled, in part, by tumour-stroma cell interactions. Further studies are
needed to determine the in vivo regulation of MMP-9 production from infiltrating peritumour macrophages.
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Crucial steps in tumour invasion and metastases are the
breaching of the basement membrane (BM) and degradation
of the extracellular matrix (ECM) (Liotta et al., 1991;
Matrisian, 1992). These processes are likely to involve
numerous proteolytic enzymes, including matrix metallopro-
teinases (MMPs), a family of extracellular matrix-degrading
enzymes (Liotta et al., 1991). To date, at least 14 members of
the MMP family have been described by substrate specificity
(Birkedal-Hansen, 1995). Based on substrate preference,
MMPs can be subclassified into interstitial collagenases
(MMP-1, MMP-8 and MMP-13), type IV collagenases/
gelatinase (MMP-2 and MMP-9), stromelysins (MMP-3 and
MMP-10), membrane-type MMPs [MT-MMP1 (Sato et al.,
1994), MT-MMP2 (Will and Hinzmann, 1995), MT-MMP3
(Takino et al., 1995) and MT-MMP4 (Puente et al., 1996)].
However, several MMPs including, stromelysin 3 (MMP-11)
(Noel et al., 1995) and macrophage metalloelastase (MMP-
12) (Woessner, 1994; Birkedal-Hansen, 1995) do not appear
to belong to any one group.
An important role for MMPs in invasion and metastases is
supported by studies demonstrating a correlation between
elevated MMP levels and the metastatic phenotype in cell
cultures (Ballin et al., 1988; Moll et al., 1990; Turpeenniemi-
Hujanen et al., 1985; Yamagata et al., 1988), animal models
(Nakajima et al., 1990) and several human tumours (Muller
et al., 1991; McDonnell et al., 1991; Hamdy et al., 1994; Levy
et al., 1991; Stearns and Wang, 1993; Rao et al., 1993;
Yoshimoto et al., 1993; Kossakowska et al., 1993; Brown et
al., 1993; Naylor et al., 1994).
Since type IV collagen is a major component of BM, the
72 kDa (MMP-2) and 92 kDa (MMP-9) type IV collagenase
are of particular interest. In order to understand further in
vivo type IV collagenase regulation, knowledge of the in vivo
sources of MMP-2 and MMP-9 production is essential.
However, owing to conflicting reports localising MMP-2
mRNA to peritumour stromal fibroblasts (Poulsom et al.,
1992; Pyke et al., 1993) and MMP-2 protein to CRC cells
themselves (Levy et al., 1991), the cellular origin of MMP-2
within CRC specimens remains unclear. Similarly, although
microdissection studies on human CRC specimens localise
increased pro-MMP-9 enzyme to the invasive CRC edge
(Emmert-Buck et al., 1994), the cellular source of MMP-9
remains uncertain, since MMP-9 mRNA signals have been
localised to the peritumour stromal compartment of breast
(Tryggvason et al., 1993; Davies et al., 1993a), skin (Pyke et
al., 1992), bladder (Davies et al., 1993b) and colorectal
cancers (Pyke et al., 1993; Newell et al., 1994; Zeng and
Guillem, 1995), while MMP-9 immunostaining has been
localised within CRC cells as well as peritumour stromal
neutrophils and macrophages (Jeziorska et al., 1994).
Furthermore, in human osteoclastomas, both MMP-9 RNA
and protein have been localised to multinucleated giant cells
(Wucherpfennig et al., 1994). In order to clarify the
discrepancy in the cellular origin of CRC MMP-9, we
examined the simultaneous mRNA and protein pattern of
MMP-9 expression in human CRC specimens.
Materials and methods
Tissue preparation
Twenty-six colorectal cancers and paired normal tissue used
in this study were obtained from the operating room
immediately after resection with the approval of the
Institutional Review Board of the Memorial Sloan-Kettering
Cancer Center. They were quick frozen in liquid nitrogen and
stored at - 80°C until processed. Samples were handled and
stored under strict RNAase-free conditions. Frozen-section
tissue was embedded in OCT (Miles, Elkhart, IN, USA) and
frozen in 2-methylbutane cooled with liquid nitrogen. For in
situ hybridisation, specimens were fixed in RNAase-free 4%
paraformaldehyde overnight at 4°C, sequentially dehydrated
with 50%, 70%, 85%, 95% and 100% ethanol and embedded
in paraffin.
Northern blot hybridisation
RNA was extracted by the guanidium isocyanide-caesium
chloride methods, as previously described (Guillem et al.,
1990). Total RNA (10 jg) were electrophoresed on 1.0%
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agarose-formaldehyde gel and blotted onto a Duralon-UV
membrane (Stratagene). MMP-9 DNA probes were radio-
labelled with [32P]dCTP by the random primer technique. A
28S oligo probe was used as an internal control for equal
RNA loading and ethidium bromide staining of gels to
confirm equal RNA transfer.
In situ hybridisation
Our techique for MMP-9 in situ hybridisation has been
previously described in detail (Zeng and Guillem, 1995).
Briefly, the sense and antisense transcripts were prepared
from a human MMP-9 cDNA insert (1059 bp extending from
nucleotides 7 to 1066) subcloned in Bluescript KS
(Stratagene). The MMP-9 sense probe was generated by T3
polymerase following digestion with XbaI, while the antisense
probe was generated by T7 polymerase after EcoRI template
digestion respectively. Transcribed RNA was labelled with
C[35S]UTP (1200 Ci mmol-1, DuPont NEN). DNA template
was removed by incubating with RNAase-free DNAase.
tRNA (10 jug) was added and samples were extracted with
phenol-chloroform. RNA probes were hydrolysed with
sodium carbonate buffer, pH 10.2, for 60 min at 60°C,
neutralised and ethanol precipitated.
Paraffin sections (5-10,M thick) were dried, deparaffi-
nised and redehydrated. Slides were incubated with
proteinase K (100 jug ml-1), washed in 2 mg ml-1 glycine
(w/v), and lastly, washed in triethanolamine buffer containing
0.25% acetic anhydride. Sections were covered with 35S-
labelled RNA probe and sealed with a coverslip and
incubated at 57°C overnight. After hybridisation, slides were
washed in 4 x saline sodium citrate (SSC) for 1 h and then in
2 x SSC, 50% formamide, 10 mM DTT solution for 40 min at
68°C. Slides were then treated with 20 ,ug ml-' RNAase-A in
20 mM Tris, pH 7.5, 0.5 M sodium chloride, 1 mM EDTA at
37°C for 30 min, followed by washing in the same buffer
without RNAase-A for 30 min. The final washes were in
2 x SSC, 50% formamide, 1 mM DTT for 40 min at 68°C,
2 x SSC for 5 min at room temperature and 0.1 x SSC for
15 min at 50°C. Slides were dehydrated through graded
ethanol and air dried.
Autoradiographic detection of the hybrids was carried out
by dipping in Kodak NTB-2 emulsion (Eastman Kodak,
Rochester, NY, USA) at 42°C under safelight and dried.
Slides were developed and fixed after 10 -14 days exposure.
Tissue sections were counterstained with haematoxylin and
eosin (H&E). The sections were examined by dark-field
microscopy.
Monoclonal antibody
The monoclonal antibody (MAb) MMP-9 (Ab-2) (clone 7-
1 IC) was obtained from Oncogene Science, Inc. (Manhassett,
NY, USA). This MAb is generated by immunising mice with
MMP-9 protein partially purified from the conditioned media
of PMA-stimulated HT1080 human fibrosarcoma cells
(Ramos-DeSimone et al., 1993). MMP-9 (Ab-2) recognises
the latent (92 kDa) form of human MMP-9. The active
(82 kDa) form of human MMP-9 cannot be recognised by
this antibody (Ramos-DeSimone et al., 1993). MAb MMP-9
(Ab-2) was used for both Western blot and immunohisto-
chemistry. The anti-human macrophage monoclonal anti-
body, CD-68 (KP-1), was obtained from Dako Corporation
(Glostrup, Denmark). This antibody is known to react with
macrophages in a wide variety of human tissues, including
Kupffer's cells and macrophages in the red pulp of the spleen,
in the lamina propria of the gut, in lung alveoli and in bone
marrow (Pulford et al., 1989). However, not all haemato-
poietic cells react with KP1 antibody (Thalmeier et al., 1994).
Western blot analysis
The tissue was homogenised in Tris buffer (50 mM Tris-HCl,
pH 7.5, containing 75 mM sodium chloride) and centrifuged
at 5000 xg for 20 min as previously described (Zeng et al.,
1994a). The supernatant of tumour and paired normal
mucosa (25 ,ug) were electrophoresed on a 8% sodium
dodecyl sulphate-polyacrylamide gel electrophoresis gel using
a MINIGEL apparatus (Bio-Rad, Richmond, CA, USA).
Separated proteins were transferred to nitrocellulose mem-
branes (Amersham, Bucks, UK) in Tris/glycine buffer
(2.5 mM Tris, 192 mM glycine and 20% methanol) at 4°C
and 100 V using a MINI system. Non-specific binding sites
were blocked for 1 h at room temperature in 10 mM Tris
buffer containing 150 mm sodium chloride and 0.5% Tween
20 (TBS-T) with 4% bovine serum albumin (BSA). The blots
were incubated overnight at 4°C in a 1:500 dilution of MMP-
9 MAb Ab-2. The blot was washed several times with TBS-T,
followed by an incubation step with horseradish peroxidase-
labelled anti-rabbit antibody (1:5000 in TBS-T for 30 min at
room temperature). After washing with TBS-T, an enhanced
chemiluminescence detection system (ECL, Amersham) was
used. For molecular weight determination, ECL protein
molecular weight and rainbow coloured protein molecular
weight markers (Amersham) were used.
Immunohistochemistry
For immunohistochemical staining, the slides were processed
by use of the Vectastain ABC Elite kits (Vector Laboratories,
Inc., Burlingame, CA, USA) according to the manufacturer's
protocol as previously described (Zeng et al., 1994b).
Immediately before staining, frozen sections were fixed in 4°C
acetone then rinsed with phosphate-buffered saline (PBS).
For the reduction of non-specific background staining,
slides were incubated with diluted normal blocking serum for
20 min at room temperature. The serum was drained off and
sections were incubated with the MAb MMP-9 (Ab-2) at a
concentration of 200 ng ml-1 at 4°C overnight. After
washing, the slides were incubated with diluted biotinylated
secondary antibody solution for 30 min, rinsed with PBS and
then incubated with Vectastain Elite ABC reagent for 30 min.
Following this, tissue sections were rinsed in PBS and
immunostaining was developed by immersion in 0.06% 3.3'-
diaminobenzidine tetrahydrochloride (DAB) solution dis-
solved in 0.5% Triton-X/PBS for 4 min. Sections were
counterstained with modified Horris-Haematoxylin (Fisher)
and 0.3% ammonia water and passed through graded
alcohols and xylene to dehydrate. Slides were then observed
by conventional light microscopy.
Tissue sections adjacent to those used for MMP-9 staining
were stained by a MAb KP-1 (CD-68).
Densitometric quantitation
MMP-9 RNA and protein levels were quantitated by
measuring the intensities of the appropriate autoradio-
graphic bands using LKB XL laser densitometry (Pharma-
cia LKB Biotechnology, Uppsala, Sweden).
The RNA results were expressed as the fold-increase of a
2.8 kilobase MMP-9 transcript in tumours to that in the
paired normal tissues. The 28S transcript was used as an
internal control:
T/N (Tumour/Normal mucosa)= TMMpg:T28s/NMMpg:N28S
The MMP-9 protein levels are expressed as the fold-
increase in expression of the 92 kDa bands in tumour relative
to that measured in the corresponding adjacent normal
mucosa.
Differences ofboth RNA and protein levels between tumour
and paired normal tissue were analysed by Student's t-test.
Results
Determination of tumour-normal MMP-9 RNA level
Total cellular RNA of human CRC and paired adjacent
normal mucosa from 26 CRC patients was examined for
expression of MMP-9 RNA by Northern blot hybridisation.Colocalisation of MMP-9 mRNA and protein in colon cancer stroma
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Figure 1 is a representative Northern blot hybridisation of
five CRC patients. The 2.8 kb MMP-9 transcript was
strongly expressed in tumour compared with the extremely
low levels noted in normal mucosa. Densitometric analyses of
blots indicated that MMP-9 was overexpressed in all primary
CRCs when compared with corresponding normal mucosa.
The T/N fold-increase of MMP-9 RNA ranged from 1.3 to
25.7 with a mean+standard deviation (s.d.) of 9.7+7.1.
MMP-9 RNA expression was significantly increased in
primary CRC relative to adjacent normal mucosa (P<0.001).
Determination of tumour-normal MMP-9 protein level
The expression of MMP-9 protein in the CRC was detected
by Western blot analysis. A 92 kDa band representative of
MMP-9 protein was increased in the tumour compared with
normal mucosa (Figure 2). Based upon MMP-9 protein
densitometric quantitation, the mean MMP-9 protein tumour
to normal mucosa fold-increase was 7.1 +3.9 (mean+s.d.)
(P< 0.001).
Cellular localisation ofMMP-9 mRNA by in situ hybridisation
The cellular localisation of MMP-9 RNA within CRC tissues
was examined by in situ hybridisation using an antisense MMP-
9 RNAprobe. Eighteen out of26 (69.2%) CRCshaddetectable
signals for MMP-9 mRNA. The predominance of MMP-9-
positive cells was limited to the interface between tumour and
surrounding normal mucosa and shows a punctate pattern of
localisation (Figure 3a and b). MMP-9-positive signals were
located in stromal cells encircling the tumourepithelial cells but
not in tumour cells themselves (Figure 3c and d). No
Mr(kDa) T N I T N Ir T N T N
I
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Figure 1 A representative Northern blot hybridisation of five
colorectal cancer patients. MMP-9 expression is higher in primary
tumour (T) than in adjacent normal mucosa (N). Total RNA was
first hybridised with an MMP-9 cDNA probe (top). The blot was
subsequently stripped and rehybridised to a 28S probe as an
internal control (bottom).
Figure 2 Western blot analysis of MMP-9 protein in colorectal
cancer. Tumour (T) and normal mucosa (N) extracts from each
patient were separated on an 8% SDS-PAGE gel and transferred
to a nitrocellulose membrane, which was incubated with an anti-
MMP-9 monoclonal antibody and visualised as described in
Materials and methods. The position of MMP-9 is noted by
arrows.
Figure 3 In situ hybridisation of MMP-9 mRNA in colorectal cancer. Sections were hybridised with a 35S-labelled anti-sense RNA
probe specific for MMP-9. Microphotographs demonstrate MMP-9 mRNA are located in malignant tumour stroma, not in cancer
cells themselves. Paired dark-field (a) and bright-field (b) display that MMP-9 mRNA are most abundant in the interface between
tumour (T) and normal mucosa (M) and show a punctate pattern of localisation. Paired bright (c) and dark-field (d)
photomicrographs reveal that MMP-9 RNA signals within the stroma are circular in shape. Scale bars = 100 gim.
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Figure 4 Immunohistochemical localisation of MMP-9 protein in colorectal cancer and normal mucosa. a, Normal colon mucosa
without any MMP-9 staining, scale bar= 50gm. b, Higher magnification of a, scale bar=25jum. c, MMP-9 protein concentrated at
the invading front between tumour and normal mucosa, scale bar= lOOpm. d, Higher magnification of area bordered by arrows in c,
scale bar =50,um. e, MMP-9 protein is located in the tumour stroma and not in cancer cells, scale bar= 50,um. f, Higher
magnification of area bordered by arrows in e; MMP-9 protein-positive cells located within peritumour stroma have a macrophage-
like morphology, scale bar=25,m.
overexpression was detected in adjacent normal mucosa. In situ
hybridisation using an MMP-9 sense probe revealed only a
background level of signals (figures not shown).
Cellular localisation of MMP-9 protein by
immunohistochemstry
Immunohistochemical staining with an anti-MMP-9 mono-
clonal antibody revealed positive brown signals in most CRC
tissue sections. Figure 4 demonstrates typical results with
anti-MMP-9 MAb in normal colonic mucosa and CRC tissue
sections. Figure 4a and b (higher magnification of Figure 4a)
demonstrate absence of staining in normal mucosa. Control
sections processed with preimmune serum also did not stain
(data not shown).
The pattern of MMP-9 protein cellular localisation in
CRC was similar to the MMP-9 mRNA. Figure 4c, d, e and f
demonstrate the typical pattern of tumour stroma MMP-9
staining without tumour cell staining. A colon cancer with
surrounding normal mucosa (Figure 4c and d higher
magnification, bordered by arrows in Figure 4c) demon-
strates MMP-9 antigen concentration at the invading front
between tumour and normal mucosa. Figure 4e and f (higher
magnification, bordered by arrows in Figure 4e) further
emphasises that MMP-9 protein-positive cells are located
principally in the peritumour stroma. Higher magnification
(Figure 4d and f) reveals that MMP-9-positive cells have a
macrophage-like morphology.
To identify the cells expressing MMP-9 protein, serial
sections from ten CRC samples were examined immunohis-
tochemically with both MMP-9 and macrophage-specific
antibodies (CD-68) (Pulford et al., 1989). Figure 5a and c
reveals anti-MMP-9 MAb and anti-macrophage MAb
staining respectively. As noted, MMP-9-positive cells and
macrophages have a similar distribution. At higher magnifi-
cation (Figure 5b and d), MMP-9-positive cells with a
macrophage-like morphology correspond directly with the
cells staining positive for macrophages.Colocalisation of MMP-9 mRNA and protein in colon cancer stroma
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Figure 5 Confirmation of MMP-9 protein within macrophages by immunohistochemical staining. Serial sections (a and c) of a
colon cancer stained with anti-MMP-9 MAb and macrophage-specific MAb antibody KPI (CD-68) respectively. (a) MMP-9
protein-positive cells, scale bar= I00gm. (b) Higher magnification of bordered area in a reveals MMP-9-positive cells with a
macrophage-like morphology, scale bar=25tim. (c) Macrophage-positive cells identified in an adjacent section to a, scale
bar= 100gm. d, Higher magnification of same field as shown in a, scale bar=25,m. Arrows indicate that cells positive for anti-
MMP-9 MAb are also positive for anti-macrophage MAb.
Discussion
Based upon both Northern and Western blot data, as well as
in situ hybridisation and immunohistochemical staining, our
results provide convincing evidence that MMP-9 is signifi-
cantly overexpressed in CRC and that the sites of production
are the peritumour stromal cells rather than the cancer cells
themselves. These results, along with our previous zymo-
graphic studies demonstrating increased levels of active
MMP-9 (82 kDa) in CRC specimens from patients with
metastases (Zeng et al., 1995), suggest an important role for
MMP-9 production in CRC invasion and metastases.
In addition to studies demonstrating a correlation between
MMP-9 expression and invasion and metastases (Ballin et al.,
1988; Moll et al., 1990; Turpeenniemi-Hujanen et al., 1985;
Yamagata etal., 1988), a recent transfection study directly links
MMP-9expression tothemetastaticphenotype (Bernhard etal.,
1994). Although in vitro, TGF-a, EGF and TGF-,B up-regulate
MMP-9 expression (Birkedal-Hansen et al., 1993), and natural
tissue inhibitor proteins, such as tissue inhibitor ofmetallopro-
teinase (TIMP) (Liotta et al., 1991; Matrisian, 1992) inhibit
MMP activity, the in vivo regulation of MMP-9 remains
unknown. This is, in part, owing to the uncertainty of the
cellular origin ofMMP-9 and its site ofactivation.
In vitro, a variety of cell types including fibroblasts,
endothelial cells, keratinocytes, macrophages and eosinophils
produce MMP-9 (Werb and Alexander, 1993; Saarialho-Kere
et al., 1993). In human squamous cell carcinomas, Pyke et al.
(1992) have demonstrated that MMP-9 mRNA is expressed by
stromal macrophages, whereas Stahle-Backdahl and Parks
(1993) noted that tissue eosinophils produce MMP-9. In human
CRC, data from Pyke et al. (1993) and our own (Zeng and
Guillem, 1995) demonstrate that MMP-9 mRNA may be
produced by peritumour macrophages. In the present study, we
demonstrate that MMP-9 protein, detected with an MMP-9
monoclonal antibody, also localises to the peritumour
macrophages. The lack of a complete concordance between
the immunohistochemical staining pattern of MMP-9-positive
cells and macrophages suggests that either serial adjacent
sections are not 100% morphologically identical or other
stromal cells, such as neutrophils (Jeziorska etal., 1994; Nielsen
et al., 1996), eosinophils (Stahle-Backdahl and Parks, 1993),
fibroblasts or endothelial cells may also be producing MMP-9.
Although the in vivo regulation of MMPs remains
undefined, the localisation of several MMPs to tumour
stromal cells rather than tumour cells themselves (Pyke et
al., 1992; 1993; Cottam and Rees, 1993; Davies et al. 1993a,b
Canete-Soler et al., 1994; Zeng and Guillem, 1995) suggests
that stromal cells may be involved in this process. Basset et
al. (1990) and Wolf et al. (1993) first demonstrated both
mRNA and protein expression of MMP-11 (stromelysin) in
the tumour stroma of human breast carcinoma. However,
current evidence suggests that the mRNA and protein
expression of other MMPs may be in either tumour or
stromal cells. In CRC, matrilysin (MMP-2) mRNA is
produced by benign and malignant cells (Cottam and Rees,
1993). In contrast, mRNA of other MMPs, such as MMP-2,
3, 7, 9, 11 appear to be restricted to tumour stromal cells
(Pyke et al., 1993; Cottam and Rees, 1993; Zeng and
Guillem, 1995). Although MMP-2 mRNA has been found
exclusively in fibroblasts, MMP-2 protein has been localised
to the surface of cancer cells (Pyke et al., 1992, 1993).
Discrepancies between MMP-2 mRNA and protein cellular
expression suggest distinct sites of MMP-2 RNA productionocakabon of NW-9 mRNA and protek in coloncancerstroma
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and MMP-2 protein utilisation (Levy et al.. 1991; Mackay et
al.. 1992). This concept is supported by the detection of an
MMP-2 cell surface binding protein on cancer cell lines
(Emonard et al.. 1992), as well as a transmembrane MMP
(MT-MMP) capable of activating MMP-2 (Sato et al., 1994).
Although evidence supports a complex membrane-
associated regulation of MMP-2, involving TIMPs, the
recently described membrane activators (MT-MMP) and a
cell surface MMP-2 binding protein (Birkedal-Hansen. 1995;
Young et al., 1995; Yu et al., 1995), less is known about
MMP-9 activation. In *itro. stromelysin-I (MMP-3), TIMP-2,
plasmin. kallikrein (Birkedal-Hansen, 1995), and most
recently, MMP-2 (Fridman et al., 1995), have been shown
to activate MMP-9. However, the localisation of MMP-9
mRNA to the stroma of breast (Davies et al., 1993a), bladder
(Davies et al.. 1993b) and skin cancer (Pyke et al., 1992) and
CRC (Pyke et al.. 1993; Zeng and Guillem, 1995) suggests a
stromal source of MMP-9 in several human cancers. Our
present results demonstrating colocalisation of both MMP-9
mRNA and protein to pentumour macrophages suggest that
peritumour macrophages are both a source of MMP-9
production and a site of localisation and, therefore, a
possible site of utilisation.
The localisation of MMP-9 around tumour blood vessels
(Davies et al.. 1993b) also suggests that MMPs may facilitate
angiogenesis via enhanced ECM turnover. Furthermore, the
localisation of MMP-9 signals to the interface between cancer
and stromal cells suggests probable cancer-stromal cell
interactions in the regulation of macrophage MMP-9
production. Although certain factors produced from cancer
cells. such as tumour collagenase-stimulating factor (TCSF).
can stimulate fibroblast MMP-2 production (Kataoka et al..
1993), it does not appear to stimulate MMP-9 production.
However, the observation that mitogens, such as lipopolv-
saccharide (LPS), can stimulate the production of both
MMP-2 and MMP-9 from murine peritoneal macrophages
(Sledge et al., 1995), as well as our recent coculture
experiments demonstrating induction of monocyte-MMP
release by metastatic CRC cells (Swallow et al., 1996).
support the notion that in vivo CRC cells may activate
macrophage MMP production in a paracrine-like manner.
Alternative explanations include CRC cell-mediated chemoat-
traction of activated macrophages, which express MMP-9. or
induction of MMP-9 gene expression in resident macrophages
(Mantovani and Semeraro. 1995).
In summary, we have demonstrated that MMP-9 RNA and
protein expression are significantly elevated in CRC when
compared with corresponding normal mucosa. The distribu-
tion of MMP-9 mRNA and protein in CRC tissues is similar
and appears to localise to macrophages at the interface between
cancer cells and surrounding normal tissue. Further studies are
needed to determine the in vivo regulation of MMP-9
production from infiltrating peritumour macrophages as well
as to delineate cancer-stromal cellular interactions.
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